Carlo Gambacorti-Passerini

Carlo Gambacorti-Passerini

UNVERIFIED PROFILE

Are you Carlo Gambacorti-Passerini?   Register this Author

Register author
Carlo Gambacorti-Passerini

Carlo Gambacorti-Passerini

Publications by authors named "Carlo Gambacorti-Passerini"

Are you Carlo Gambacorti-Passerini?   Register this Author

100Publications

2846Reads

13Profile Views

The role of bosutinib in the treatment of chronic myeloid leukemia.

Future Oncol 2020 01 13;16(2):4395-4408. Epub 2019 Dec 13.

Department of Medicine & Surgery, University of Milano-Bicocca, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0555DOI Listing
January 2020

Acute myeloid leukaemia niche regulates response to L-asparaginase.

Br J Haematol 2019 08 1;186(3):420-430. Epub 2019 May 1.

M. Tettamanti Research Centre, Department of Paediatrics, University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15920DOI Listing
August 2019

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Neoplasia 2018 05 30;20(5):467-477. Epub 2018 Mar 30.

Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Clinical Research Unit, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915992PMC
May 2018

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers (Basel) 2018 Feb 28;10(3). Epub 2018 Feb 28.

Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin 10124, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10030062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876637PMC
February 2018

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

J Clin Oncol 2018 01 1;36(3):231-237. Epub 2017 Nov 1.

Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore, Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, London, United Kingdom; Philipp le Coutre, Charité-Universitätsmedizin Berlin, Berlin; Andreas Hochhaus, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena; Tim H. Brümmendorf, Universitätsklinikum RWTH Aachen, Aachen, Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Eric Leip, Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966023PMC
January 2018

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Am J Hematol 2017 10 17;92(10):E623-E625. Epub 2017 Aug 17.

School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24865
Publisher Site
http://dx.doi.org/10.1002/ajh.24865DOI Listing
October 2017

RET kinase inhibitors: a review of recent patents (2012-2015).

Expert Opin Ther Pat 2017 Jan 26;27(1):91-99. Epub 2016 Sep 26.

c School of Pharmaceutical Sciences , University of Geneva , Geneva , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1238073DOI Listing
January 2017

How "precise" is precision medicine in hematology?

Haematologica 2017 01;102(1):4-6

Hematology, School of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, Monza, Italy

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2016.155267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210227PMC
January 2017

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

J Cancer 2017 1;8(1):140-145. Epub 2017 Jan 1.

School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy;; Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.15838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264050PMC
January 2017

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.

J Hematol Oncol 2016 07 29;9(1):63. Epub 2016 Jul 29.

Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Ospedale "R. Binaghi", Via Is Guadazzonis, 3, 09126, Cagliari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-016-0293-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966800PMC
July 2016

Chronic myeloid leukemia: Second-line drugs of choice.

Am J Hematol 2016 Jan;91(1):67-75

Department of Medicine and Surgery, University of Milano-Bicocca, Section of Hematology, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24247DOI Listing
January 2016

ALK inhibitors for clinical use in cancer therapy.

Front Biosci (Elite Ed) 2016 Jan 1;8:46-60. Epub 2016 Jan 1.

Department of Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20052 Monza, Italy,

View Article

Download full-text PDF

Source
January 2016

Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

N Engl J Med 2016 Jan;374(1):95-6

University of Milan-Bicocca, Monza, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1511045DOI Listing
January 2016

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.

Exp Hematol 2015 Dec 22;43(12):1015-1018.e1. Epub 2015 Aug 22.

Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2015.08.004DOI Listing
December 2015

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

J Hematol Oncol 2015 Jul 7;8:81. Epub 2015 Jul 7.

Department of Health sciences, University of Milano-Bicocca, S.Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-015-0179-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491863PMC
July 2015

Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.

JAMA Oncol 2015 May;1(2):143-4

Department of Health Sciences, University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2015.50DOI Listing
May 2015

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Mol Cancer Res 2015 Apr 31;13(4):699-712. Epub 2015 Mar 31.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-14-0422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398615PMC
April 2015

How I treat newly diagnosed chronic myeloid leukemia in 2015.

Am J Hematol 2015 Feb 24;90(2):156-61. Epub 2014 Nov 24.

Department of Health Sciences, University of Milano-Bicocca, Section of Hematology, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23887DOI Listing
February 2015

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.

Am J Hematol 2014 Oct 31;89(10):E184-7. Epub 2014 Jul 31.

Department of Health Sciences, University of Milano-Bicocca, via Cadore 48, Monza, Italy; San Gerardo Hospital, Clinical Research Unit, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23804DOI Listing
October 2014

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Crit Rev Oncol Hematol 2014 Jun 17;90(3):181-9. Epub 2013 Dec 17.

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.12.010DOI Listing
June 2014

Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.

Expert Opin Pharmacother 2014 Apr 30;15(5):701-10. Epub 2014 Jan 30.

University of Milano-Bicocca, Department of Health Sciences , Via Cadore 48, 20900 Monza , Italy

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2014.88
Publisher Site
http://dx.doi.org/10.1517/14656566.2014.882898DOI Listing
April 2014

Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.

Bioorg Med Chem 2014 Feb 10;22(4):1303-12. Epub 2014 Jan 10.

Université de Lyon, Laboratoire Chimie Organique 2-Glycochimie, ICBMS, UMR-5246, CNRS-Université Claude Bernard Lyon 1, Bât. 308 CPE Lyon, 43 Bd du 11 Novembre 1918, F-69622 Villeurbanne, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2014.01.007DOI Listing
February 2014

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

J Natl Cancer Inst 2014 Feb;106(2):djt378

Affiliations of authors: Department of Health Sciences, University Milano Bicocca, Monza, Italy (CGP, FF, AS, SR, MC, LMo, CM, LA, RP); Hematology Unit (CGP) and Nuclear Medicine and PET Unit (CM, LG), San Gerardo Hospital, Monza, Italy; M Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza, Italy (GG); Medical Genetics Laboratory, San Gerardo Hospital, Monza, Italy (ES); Istituto di Ricerca Pediatrico Fondazione Città della Speranza, Pediatric Clinic University of Padova, Padova, Italy (LMu); H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium (DD); Trillium Health Centre, Mississauga Site, Mississauga ON, Canada (MHK); Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria (MS); Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (RO); Hematology Institute, Beilinson Hospital, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (AMC); Department of Haematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany (MG); Hematology/Stem Cell Transplantation, Maisonneuve Rosemont/University of Montreal, Montreal, QC, Canada (LB); School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland (GC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt378DOI Listing
February 2014

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases.

Mol Genet Genomic Med 2013 Nov 7;1(4):246-59. Epub 2013 Jul 7.

Department of Health Sciences, University of Milano-Bicocca Monza, Italy ; Hematology and Clinical Research Unit, San Gerardo Hospital Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mgg3.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865592PMC
November 2013

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Mol Cell Endocrinol 2013 Sep 27;377(1-2):1-6. Epub 2013 Jun 27.

Dept. of Health Sciences, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2013.06.025DOI Listing
September 2013

Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.

Analyst 2013 Jul;138(14):3934-45

Azienda Ospedaliera Universitaria Integrata Verona, Department of Pathology and Diagnostics - Unit of Immunology, Policlinico G. Rossi, P.le L.A. Scuro, 10, I-37134, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c2an36393cDOI Listing
July 2013

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.

Mol Cancer Res 2013 Feb 13;11(2):122-32. Epub 2012 Dec 13.

Department of Health Sciences, University of Milano-Bicocca, Via Cadore 48, Monza 20900, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-12-0569DOI Listing
February 2013

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Am J Hematol 2012 Nov 9;87(11):E125-8. Epub 2012 Oct 9.

Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S. Gerardo Hospital, Monza, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23338DOI Listing
November 2012

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery.

Nucleic Acids Res 2012 Sep 8;40(16):e123. Epub 2012 May 8.

Department of Clinical Medicine, University of Milano-Bicocca, Monza, 20900, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gks394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439881PMC
September 2012